Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Operating Expenses (2022 - 2025)

Historic Operating Expenses for Coeptis Therapeutics Holdings (COEP) over the last 4 years, with Q3 2025 value amounting to $2.7 million.

  • Coeptis Therapeutics Holdings' Operating Expenses rose 2463.01% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 2064.91%. This contributed to the annual value of $10.1 million for FY2024, which is 5321.56% down from last year.
  • According to the latest figures from Q3 2025, Coeptis Therapeutics Holdings' Operating Expenses is $2.7 million, which was up 2463.01% from $4.7 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' 5-year Operating Expenses high stood at $15.7 million for Q1 2022, and its period low was $2.1 million during Q3 2024.
  • Moreover, its 4-year median value for Operating Expenses was $3.7 million (2023), whereas its average is $5.1 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 7289.29% in 2024, then soared by 6536.67% in 2025.
  • Coeptis Therapeutics Holdings' Operating Expenses (Quarter) stood at $3.0 million in 2022, then grew by 10.6% to $3.4 million in 2023, then crashed by 35.76% to $2.2 million in 2024, then grew by 23.45% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $4.7 million for Q2 2025, and $4.1 million during Q1 2025.